BM213

• Description:

  BM213 is a selective C5aR agonist, with an EC50 of 59 nM. BM213 specifically activates the C5a-C5aR1 axis, which in turn promotes neutrophil extracellular trap (NET) formation and exacerbates inflammatory responses. BM213 significantly induces ventricular dilationin, promotes myocardial ROS production, and induces cardiomyocyte apoptosis in rats. BM213 can be used for the study of myocardial ischemia/reperfusion (I/R) injury[1].

• UNSPSC:

  12352209

• Target:

  Apoptosis; Complement System; Reactive Oxygen Species (ROS)

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bm213.html

• Purity:

  99.81

• Solubility:

  H2O : 50 mg/mL (ultrasonic)

• Smiles:

  OC([C@@H](NC([C@@H](C)NC([C@H](C)NC([C@H](C)NC([C@H](CC(C)C)NC([C@@H]1CCCN1C([C@@H](NC([C@H](CC2=CC=CC=C2)NC(C)=O)=O)CCCCN[H])=O)=O)=O)=O)=O)=O)CCCNC(N)=N)=O

• Molecular Formula:

  C43H70N12O10

• Molecular Weight:

  915.09

• References & Citations:

  [1]Zhang M, et al. 13-methylpalmatine alleviates myocardial ischemia/reperfusion injury by potentially targeting the C5a-C5aR1 axis to inhibit neutrophil extracellular trap formation. Redox Biol. 2025 Aug 5;86:103802. |[2]Gorman DM, et al. Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. J Med Chem. 2021 Nov 25;64 (22) :16598-16608.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2891606-02-1]